David M. Mott

CIK: 0001219871

Transaction Breakdown

Open Market Buys (P)9 (25.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)3 (8.3%)

Derivative conversions

Awards (A)9 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)15 (41.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

NVAX

NOVAVAX INC

Director

ARDX

ARDELYX, INC.

Director

MRSN

Mersana Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (36 total)

NVAX
NOVAVAX INC
Jun 20, 2026
Exercise(M)
Direct
18.9K shares-
NVAX
NOVAVAX INC
Jun 18, 2026
Award(A)
Restricted Stock Units
Direct
14.2K shares-
NVAX
NOVAVAX INC
Jun 18, 2026
Award(A)
Stock Option (Right to Buy)
Direct
21.3K shares-
ARDX
ARDELYX, INC.
Jun 16, 2026
Award(A)
Direct
20.3K shares-
ARDX
ARDELYX, INC.
Jun 16, 2026
Award(A)
Direct
26.5K shares-
ARDX
ARDELYX, INC.
Feb 20, 2026
Purchase(P)
Direct
333.3K shares at avg. $5.84$1.9M
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
1K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
1K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
1K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
400 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
264 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
2.5K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Tender Offer(U)
Indirect
383 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
788 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
368 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
181 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
740 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
2.2K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
734 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
1.8K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Tender Offer(U)
Direct
23.5K shares-
NVAX
NOVAVAX INC
Jun 20, 2025
Award(A)
Restricted Stock Units
Direct
18.9K shares-
NVAX
NOVAVAX INC
Jun 20, 2025
Award(A)
Stock Option (Right to Buy)
Direct
28.3K shares at avg. $6.42-
ARDX
ARDELYX, INC.
Jun 18, 2025
Award(A)
Direct
41.6K shares-
ARDX
ARDELYX, INC.
Jun 18, 2025
Award(A)
Direct
31.2K shares-

		Type	Shares	Price		Ownership
Jun 20, 2026	NVAX NOVAVAX INC	Exercise(M)	18,880	-	$0	Direct
Jun 18, 2026	NVAX NOVAVAX INC	Award(A) Restricted Stock Units	14,180	-	-	Direct
Jun 18, 2026	NVAX NOVAVAX INC	Award(A) Stock Option (Right to Buy)	21,270	-	-	Direct
Jun 16, 2026	ARDX ARDELYX, INC.	Award(A)	20,282	-	$0	Direct
Jun 16, 2026	ARDX ARDELYX, INC.	Award(A)	26,455	-	$0	Direct
Feb 20, 2026	ARDX ARDELYX, INC.	Purchase(P)	333,333	$5.84	$1,946,331	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	1,002	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	1,000	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	1,011	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	400	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	264	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	2,460	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Tender Offer(U)	383	-	$0	Indirect
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	788	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	368	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	181	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	740	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	2,200	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	734	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	1,800	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Tender Offer(U)	23,546	-	$0	Direct
Jun 20, 2025	NVAX NOVAVAX INC	Award(A) Restricted Stock Units	18,884	-	-	Direct
Jun 20, 2025	NVAX NOVAVAX INC	Award(A) Stock Option (Right to Buy)	28,326	$6.42	-	Direct
Jun 18, 2025	ARDX ARDELYX, INC.	Award(A)	41,551	-	-	Direct
Jun 18, 2025	ARDX ARDELYX, INC.	Award(A)	31,163	-	-	Direct

1-25 of 36 transactions

About MOTT DAVID M

MOTT DAVID M (SEC CIK 0001219871) files insider reports with the SEC as Director of NOVAVAX INC (NVAX), Director of ARDELYX, INC. (ARDX) and Director of Mersana Therapeutics, Inc. (MRSN).

Signal8 holds 17 ownership filings by MOTT DAVID M, all Form 4s, filed between Nov 14, 2024 and Jun 23, 2026. Those filings report 36 transactions, from Nov 13, 2024 to Jun 20, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on MOTT DAVID M's filings is in WALTHAM, MA.

Recent filings by MOTT DAVID M

Jun 20, 2026: Option exercise of NVAX shares (Form 4, code M).
Jun 18, 2026: Grants or awards of NVAX derivative securities (2 lines, Form 4, code A).
Jun 16, 2026: Grants or awards of ARDX shares (2 lines, Form 4, code A).
Feb 20, 2026: Open-market purchase of ARDX shares (Form 4, code P).
Jan 6, 2026: Disposition to issuer transactions of MRSN derivative securities (6 lines, Form 4, code D).

Other insiders filing for NOVAVAX INC (NVAX)

Rodgers Richard J, Director
King Rachel K., Director
DOUGLAS RICHARD, Director
MCGLYNN MARGARET G, Director
Alton Gregg H, Director
Shiver John W., Director

How to read Form 4 transaction codes